Skip to main content

Oriol de Fabregues-Boixar Nebot

I am a neurologist, Head of the Movement Disorder Unit of the Neurology Service. Attention to Parkinson's, dystonia and other neurodegenerative diseases has been one of the challenges that attracted me to Neurology. With this vocation I have attended hundreds of patients with a personalized dedication, introducing new treatments and diagnostic means, and carrying out clinical, epidemiological, therapeutic and basic research work; In short, with an innovative, and enthusiastic attitude.

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
Neurology
General Hospital

Oriol de Fabregues-Boixar Nebot

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
Neurology
General Hospital

I am a neurologist, Head of the Movement Disorder Unit of the Neurology Service. Attention to Parkinson's, dystonia and other neurodegenerative diseases has been one of the challenges that attracted me to Neurology. With this vocation I have attended hundreds of patients with a personalized dedication, introducing new treatments and diagnostic means, and carrying out clinical, epidemiological, therapeutic and basic research work; In short, with an innovative, and enthusiastic attitude.

I have my degree in Medicine & Surgery at UB and Doctorate in Neuroscience from the UAB, where I am Associate Professor of Medicine at the Faculty of Medicine.
I specialized in Neurology, through the MIR system, at the Vall d'Hebron University Hospital. I have been consolidated as a general neurologist at the Hospital de Sabadell Parc Tauli for 10 years. I have specialized in the field of neurodegenerative diseases and movement disorders. Since April 2008 I am the Head of the Movement Disorder Unit of the Hospital.
I am a clinical investigator of the VHIR Neurodegenerative Diseases Group. I have been a principal investigator in more than 50 clinical trials and research projects. That have generated numerous publications and scientific communications. I have investigated several clinical aspects of Parkinson's disease and other movement disorders and my main lines of research are the clinical and epidemiology of Parkinson's disease and new treatments for neurodegenerative diseases. I am an expert in botulinum toxin infiltration and have pioneered a complex treatment of Parkinson's disease with a levodopa pump.
I have received about twenty awards from scientific societies and I have been distinguished as “Academic corresponent” of the Royal Academy of Medicine of Catalonia.
I have been the President of the Catalan Society of Neurology (2012-2014), Member of the Academy of Medical Sciences of Catalonia and the Balearic Islands (2015) and the Patronage of the Interuniversity Institute Foundation-InterAc Salut (2015), Vocal Teaching Director of the Spanish Society of Neurology, (2015-2017) and Vice President of the National Commission of the Specialization of Neurology

Projects

Respuesta inmune adaptativa en la enfermedad de Parkinson inducida por proteoformas de alfa-sinucleína presentes en los cuerpos de Lewy: aplicación diagnóstica y terapéutica

IP: Jordi Bove Badell
Collaborators: Oriol de Fabregues-Boixar Nebot
Funding agency: Instituto de Salud Carlos III
Funding: 134915
Reference: PI15/01937
Duration: 01/01/2016 - 31/12/2018

Estudio mutacional del gen TARDBP en las formas familiar y esporádica de ELA. Análisis de la expresión en plasma y LCR de la proteína TDP-43 como biomarcadores de la enfermedad y de su correlación con los hallazgos neuropatológicos

IP: Josep Gamez Carbonell
Collaborators: Maria Salvadó Figueras, Oriol de Fabregues-Boixar Nebot
Funding agency: Instituto de Salud Carlos III
Funding: 80465
Reference: PI10/01970
Duration: 01/01/2011 - 30/06/2014

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Alfonso Biarnes Suñe

Alfonso Biarnes Suñe

Reconstructive Surgery of the Locomotor System
Read more
Sara Martin Sastre

Sara Martin Sastre

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Martín Huerta García

Martín Huerta García

Read more
Gesualdina Busiello

Gesualdina Busiello

Predoctoral researcher
Neuroradiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.